Journal article · 2022 · Open access

Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia

Giulia Maria Giordano, Edoardo Caporusso, Pasquale Pezzella, Silvana Galderisi

Expert Review of Neurotherapeutics, 22(7), 541–555 · Published 27 June 2022 · DOI 10.1080/14737175.2022.2092402

Open PDFView at the publisherCite this paper

In brief

“Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia” is a 2022 journal article by Giulia Maria Giordano and 3 co-authors, published in Expert Review of Neurotherapeutics. OpenAlex counts 60 citations as of 20 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Expert Review of Neurotherapeutics.

Citations
60
Most cited in
2025 (17)
Field-weighted impact
5.45
References
207
Authors
4

Abstract

INTRODUCTION: Negative symptoms in schizophrenia are associated with poor response to available treatments, poor quality of life, and functional outcome. Therefore, they represent a substantial burden for people with schizophrenia, their families, and health-care systems. AREAS COVERED: In this manuscript, we will provide an update on the conceptualization, assessment, and treatment of this complex psychopathological dimension of schizophrenia. EXPERT OPINION: Despite the progress in the conceptualization of negative symptoms and in the development of state-of-the-art assessment instruments made in the last decades, these symptoms are still poorly recognized, and not always assessed in line with current conceptualization. Every effort should be made to disseminate the current knowledge on negative symptoms, on their assessment instruments and available treatments whose efficacy is supported by research evidence. Longitudinal studies should be promoted to evaluate the natural course of negative symptoms, improve our ability to identify the different sources of secondary negative symptoms, provide effective interventions, and target primary and persistent negative symptoms with innovative treatment strategies. Further research is needed to identify pathophysiological mechanisms of primary negative symptoms and foster the development of new treatments.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Giordano, G. M., Caporusso, E., Pezzella, P., & Galderisi, S. (2022). Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia. Expert Review of Neurotherapeutics, 22(7), 541–555. https://doi.org/10.1080/14737175.2022.2092402

MLA 9

Giordano, Giulia Maria, et al. “Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia.” Expert Review of Neurotherapeutics, vol. 22, no. 7, 2022, pp. 541–555. https://doi.org/10.1080/14737175.2022.2092402.

Chicago

Giordano, Giulia Maria, Edoardo Caporusso, Pasquale Pezzella, and Silvana Galderisi. 2022. “Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia.” Expert Review of Neurotherapeutics 22 (7): 541–555. https://doi.org/10.1080/14737175.2022.2092402.

Harvard

Giordano, G. M. et al. (2022) ‘Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia’, Expert Review of Neurotherapeutics, 22(7), pp. 541–555. doi:10.1080/14737175.2022.2092402.

IEEE

G. M. Giordano, E. Caporusso, P. Pezzella, and S. Galderisi, “Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia,” Expert Review of Neurotherapeutics, vol. 22, no. 7, pp. 541–555, 2022, doi: 10.1080/14737175.2022.2092402.

BibTeX

@article{giordano2022updated,
  title     = {{Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia}},
  author    = {Giordano, Giulia Maria and Caporusso, Edoardo and Pezzella, Pasquale and Galderisi, Silvana},
  journal   = {Expert Review of Neurotherapeutics},
  year      = {2022},
  volume    = {22},
  number    = {7},
  pages     = {541--555},
  doi       = {10.1080/14737175.2022.2092402},
  url       = {https://doi.org/10.1080/14737175.2022.2092402}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202211
20231212
20241515
20251717
20261515

Its field-weighted citation impact is 5.45: it has been cited 5.45 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • negative symptoms
  • schizophrenia
  • primary negative symptoms
  • persistent negative symptoms
  • secondary negative symptoms
  • treatment response
  • quality of life
  • functional outcome

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Giordano, G. M., Caporusso, E., Pezzella, P., & Galderisi, S. (2022). Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia. Expert Review of Neurotherapeutics, 22(7), 541–555. https://doi.org/10.1080/14737175.2022.2092402

How many times has this paper been cited?

60 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Expert Review of Neurotherapeutics: sign in and open the PDF from this page.

Who wrote this paper?

Giulia Maria Giordano, Edoardo Caporusso, Pasquale Pezzella, Silvana Galderisi.

What is the DOI of this paper?

10.1080/14737175.2022.2092402, permanently at https://doi.org/10.1080/14737175.2022.2092402. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.